Advances in the treatment of polymyalgia rheumatica

被引:0
作者
Iorio, Luca [1 ]
Bond, Milena [2 ]
Padoan, Roberto [1 ]
Dejaco, Christian [2 ,3 ]
机构
[1] Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy
[2] Paracelsius Med Univ, Hosp Bruneck ASAA SABES, Dept Rheumatol, Teaching Hosp, Brunico, Italy
[3] Med Univ Graz, Dept Rheumatol & Immunol, Graz, Austria
关键词
polymyalgia rheumatica (PMR); GCA-PMR spectrum disease (GPSD); oral glucocorticoids (GCs); conventional DMARDs; biologic DMARDs; target DMARDs; tocilizumab; sarilumab; rituximab; JAK inhibitors; GIANT-CELL ARTERITIS; METHOTREXATE; TOCILIZUMAB; PLACEBO;
D O I
10.1093/rheumatology/keae539
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymyalgia rheumatica (PMR) is a common inflammatory disorder affecting individuals over 50. The cornerstone of PMR treatment remains oral glucocorticoids (GCs), with initial doses tailored to the risk of relapse and comorbidities. However, relapses occur in up to 76% of cases, and long-term GC use is associated with significant toxicity, affecting up to 85% of patients. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, offer limited benefits, while recent evidence supports the use of biologics, such as tocilizumab and sarilumab, in reducing GC dependency and achieving remission. Emerging treatments, including JAK inhibitors (tofacitinib) and B-cell depletion (rituximab), show promise but require further validation. The treat-to-target (T2T) strategy is advocated for achieving sustained remission and minimizing adverse effects. New treatment options requiring rheumatological expertise are emerging, highlighting the need for specialized management, early referral, improved imaging use, and standardized definitions of remission and relapse to enhance patient care and outcomes.
引用
收藏
页码:i48 / i54
页数:7
相关论文
共 30 条
  • [1] Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series
    Adizie, T.
    Christidis, D.
    Dharmapaliah, C.
    Borg, F.
    Dasgupta, B.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (09) : 906 - 909
  • [2] 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double- blind placebo-controlled trial
    Bolhuis, Thomas E.
    Marsman, Diane E.
    den Broeder, Alfons A.
    den Broeder, Nathan
    van der Maas, Aatke
    [J]. LANCET RHEUMATOLOGY, 2023, 5 (04) : e208 - e214
  • [3] Polymyalgia rheumatica: crafting the future of a simple (but not easy!) clinical syndrome
    Bond, Milena
    Dejaco, Christian
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (03) : 271 - 273
  • [4] Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial
    Bonelli, Michael
    Radner, Helga
    Kerschbaumer, Andreas
    Mrak, Daniel
    Durechova, Martina
    Stieger, Jutta
    Husic, Rusmir
    Mandl, Peter
    Smolen, Josef S.
    Dejaco, Christian
    Aletaha, Daniel
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 838 - 844
  • [5] Prednisone plus methotrexate for polymyalgia rheumatica - A randomized, double-blind, placebo-controlled trial
    Caporali, R
    Cimmino, MA
    Ferraccioli, G
    Gerli, R
    Klersy, C
    Salvarani, C
    Montecucco, C
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (07) : 493 - 500
  • [6] Cimmino MA, 2008, CLIN EXP RHEUMATOL, V26, P395
  • [7] Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica
    De Miguel, Eugenio
    Macchioni, Pierluigi
    Conticini, Edoardo
    Campochiaro, Corrado
    Karalilova, Rositsa
    Monti, Sara
    Ponte, Cristina
    Klinowski, Giulia
    Monjo-Henry, Irene
    Falsetti, Paolo
    Batalov, Zguro
    Tomelleri, Alessandro
    Hocevar, Alojzija
    [J]. RHEUMATOLOGY, 2024, 63 (01) : 158 - 164
  • [8] Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
    Dejaco, Christian
    Kerschbaumer, Andreas
    Aletaha, Daniel
    Bond, Milena
    Hysa, Elvis
    Camellino, Dario
    Ehlers, Lisa
    Abril, Andy
    Appenzeller, Simone
    Cid, Maria C.
    Dasgupta, Bhaskar
    Duftner, Christina
    Grayson, Peter C.
    Hellmich, Bernhard
    Hocvar, Alojzija
    Kermani, Tanaz A.
    Matteson, Eric L.
    Mollan, Susan P.
    Neill, Lorna
    Ponte, Cristina
    Salvarani, Carlo
    Sattui, Sebastian Eduardo
    Schmidt, Wolfgang A.
    Seo, Philip
    Smolen, Josef S.
    Thiel, Jens
    Toro-Gutierrez, Carlos Enrique
    Whitlock, Madeline
    Buttgereit, Frank
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (01) : 48 - 57
  • [9] Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities
    Dejaco, Christian
    Brouwer, Elisabeth
    Mason, Justin C.
    Buttgereit, Frank
    Matteson, Eric L.
    Dasgupta, Bhaskar
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2017, 13 (10) : 578 - 592
  • [10] 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
    Dejaco, Christian
    Singh, Yogesh P.
    Perel, Pablo
    Hutchings, Andrew
    Camellino, Dario
    Mackie, Sarah
    Abril, Andy
    Bachta, Artur
    Balint, Peter
    Barraclough, Kevin
    Bianconi, Lina
    Buttgereit, Frank
    Carsons, Steven
    Ching, Daniel
    Cid, Maria
    Cimmino, Marco
    Diamantopoulos, Andreas
    Docken, William
    Duftner, Christina
    Fashanu, Billy
    Gilbert, Kate
    Hildreth, Pamela
    Hollywood, Jane
    Jayne, David
    Lima, Manuella
    Maharaj, Ajesh
    Mallen, Christian
    Martinez-Taboada, Victor
    Maz, Mehrdad
    Merry, Steven
    Miller, Jean
    Mori, Shunsuke
    Neill, Lorna
    Nordborg, Elisabeth
    Nott, Jennifer
    Padbury, Hannah
    Pease, Colin
    Salvarani, Carlo
    Schirmer, Michael
    Schmidt, Wolfgang
    Spiera, Robert
    Tronnier, David
    Wagner, Alexandre
    Whitlock, Madeline
    Matteson, Eric L.
    Dasgupta, Bhaskar
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (10) : 1799 - 1807